MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

42.04 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,978
Open 42.04
Bid (Size) 42.35 (1,300)
Ask (Size) 42.42 (400)
Prev. Close 42.04
Today's Range 42.04 - 42.04
52wk Range 32.53 - 57.81
Shares Outstanding 227,985,334
Dividend Yield 0.83%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
From QIAGEN N.V.
Via Business Wire

Performance

YTD
-7.0%
-7.0%
1 Month
-3.1%
-3.1%
3 Month
+4.8%
+4.8%
6 Month
+2.5%
+2.5%
1 Year
-9.2%
-9.2%

More News

Read More
QIAGEN (NYSE:QGEN) Eyes Breakout With Technical Rating 7 and Setup Rating 9 ↗
Via Chartmill
News headline image
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen (QGEN) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Immigration
News headline image
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings Immigration
News headline image
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
From QIAGEN N.V.
Via Business Wire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire

Frequently Asked Questions

Is Qiagen N.V. Common Shares publicly traded?
Yes, Qiagen N.V. Common Shares is publicly traded.
What exchange does Qiagen N.V. Common Shares trade on?
Qiagen N.V. Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Qiagen N.V. Common Shares?
The ticker symbol for Qiagen N.V. Common Shares is QGEN on the New York Stock Exchange
What is the current price of Qiagen N.V. Common Shares?
The current price of Qiagen N.V. Common Shares is 42.04
When was Qiagen N.V. Common Shares last traded?
The last trade of Qiagen N.V. Common Shares was at 10/01/26 07:00 PM ET
What is the market capitalization of Qiagen N.V. Common Shares?
The market capitalization of Qiagen N.V. Common Shares is 9.58B
How many shares of Qiagen N.V. Common Shares are outstanding?
Qiagen N.V. Common Shares has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story